Finerenone Reduces Risk of Incident HF in Patients with T2D + CKD in FIGARO-DKD Analyses

Finerenone, the nonsteroidal mineralocorticoid receptor antagonist, significantly reduced new-onset HF and improved other HF outcomes in the FIGARO-DKD trial.

Finerenone was approved by the US Food and Drug Administration (FDA) in July 2021 to reduce risk for progression of renal disease, including end stage disease, and cardiovascular outcomes, including hospitalizastion for heart failure, in adults with type 2 diabetes (T2D)-associated chronic kidney disease (CKD).

Approval was based on results from the FIDELIO-DKD trial in patients with T2D and CKD treated with maximally tolerated renin–angiotensin system blockade.

FIGARO-DKD, the second in the finerenone phase 3 trial series, evaluated finerenone safety and efficacy when added to standard of care in reducing cardiovascular morbidity and mortality. The current analyses of FIGARO-DKD excluded participants with known heart failure (HF) with reduced ejection fraction in order to evaluate the drug's impact on new-onset heart failure in addition to a range of other HF outcomes. Results, at-a-glance, below.

Reference: Filippatos G, Anker SD, Agarwal R, et al and on behalf of the FIGARO-DKD Investigators. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: Analyses from the FIGARO-DKD Trial. Circulation. Published online November 13, 2021.